Progyny, Inc. (NASDAQ:PGNY) Q3 2023 Earnings Conference Call November 7, 2023 9:00 PM ET Company Participants James Hart - IR Pete Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Jailendra Singh - Truist Securities Sarah James - Cantor Richard Close - Canaccord Allen Lutz - Bank of America David Larsen - BTIG Operator Good day, everyone, and welcome to the Progyny, Inc. Third Quarter 2023 Earnings Call. [Operator ...

Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commissi ...

Progyny, Inc. (NASDAQ:PGNY) Q2 2023 Earnings Conference Call August 3, 2023 4:45 PM ET Company Participants James Hart - IR Pete Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Michael Cherny - Bank of America Scott Schoenhaus - KeyBanc Jailendra Singh - Truist David Larsen - BTIG Operator Good day, everyone, and welcome to the Progyny, Inc. Second Quarter 2023 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, James ...

WASHINGTON, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-39100 ____________________________________________ Progyny, Inc. (Exact name of registrant as specified in its charter) ________________________ ...

Progyny, Inc. (NASDAQ:PGNY) Q1 2023 Earnings Conference Call May 8, 2023 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Sarah James - Cantor Fitzgerald Eduardo Ron - Truist Securities Anna Kruszenski - SVB Securities Michael Weisberg - Crestwood Capital Operator Good day, ladies and gentlemen and welcome t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39100 Progyny, Inc. (Exact name of registrant as specified in its charter) ...

Financial Data and Key Metrics Changes - In Q4 2022, revenue reached $214.3 million, reflecting a growth of 68% compared to the previous year, while full-year revenue grew 57% to $786.9 million [22][23] - Adjusted EBITDA for Q4 more than doubled to $33 million, yielding a margin of 15.4%, and for the full year, adjusted EBITDA increased 87% to $125.7 million, with a margin of 16% [33][34] - Operating cash flow in Q4 was $51.5 million, the highest quarterly figure ever, leading to a record $80.4 million for the full year [35][36] Business Line Data and Key Metrics Changes - Medical revenue increased 60% in Q4 to $143 million and grew 43% for the full year to $510 million, driven by a higher number of clients and covered lives [28] - Pharmacy revenue surged 86% in Q4 to $71.2 million and grew 91% for the full year to $277 million, with an increase in clients utilizing Progyny Rx [28] - A record 12,200 ART cycles were performed in Q4, a 60% increase from the same period in 2021, while full-year ART cycles grew nearly 50% [29] Market Data and Key Metrics Changes - The company ended Q4 with 288 clients, representing an average of 4.7 million covered lives, compared to 191 clients and 2.9 million covered lives a year ago, reflecting a 60% growth in lives [23] - The client base is diversified across more than 40 industries, with no single industry comprising more than 20% of the member base [27] - The company maintained a near 100% retention rate among existing clients for the seventh consecutive year, with over 25% of clients increasing their Progyny program for 2023 [9][10] Company Strategy and Development Direction - The company aims to capitalize on the increasing demand for family-building benefits, with a focus on expanding its services and market penetration [12][20] - Progyny was selected by the Children's Hospital Association as the exclusive preferred partner for fertility and family-building services, indicating strong market positioning [16][18] - The company plans to enhance services related to preconception, maternity, and male infertility, reflecting a commitment to comprehensive family-building solutions [42][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining momentum from the previous year into 2023, citing strong early activity in the selling season [20][40] - The macroeconomic environment, including inflation and potential recession, has not significantly impacted client decisions regarding fertility benefits [10][12] - The company anticipates revenue growth of 27% to 31% for 2023, projecting between $1 billion to $1.03 billion in revenue [37] Other Important Information - The company achieved a gross profit of $44.5 million in Q4, yielding a gross margin of 20.8%, and for the full year, gross profit increased 49% to $167 million [30][31] - The company has no debt and ended the year with approximately $274 million in working capital, including $189 million in cash and marketable securities [36] Q&A Session Summary Question: What are the expectations for early starts in the selling season? - Management indicated that guidance includes early wins but does not expect outsized impacts from these early starts compared to the previous year [62] Question: How is the company addressing provider retention and reimbursement rates? - Management reported no issues with provider retention and indicated that they expect to maintain flat to slightly down costs for clients, differentiating from industry trends [69][70] Question: What growth should be expected in the pharmacy benefit segment? - While specific growth rates for pharmacy and medical segments are not broken out, pharmacy growth is expected to be higher but will start to converge with medical growth rates [80]

Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Com ...

Progyny, Inc. (NASDAQ:PGNY) Q3 2022 Earnings Conference Call November 3, 2022 4:45 PM ET Company Participants James Hart - VP, IR Peter Anevski - CEO Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Glen Santangelo - Jefferies Sarah James - Barclays Stephanie Davis - SVB Securities Deb Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, and welcome to the Progyny, Inc. Third Quarter 2022 Earnings Call. ...

Progyny, Inc. (NASDAQ:PGNY) Q2 2022 Earnings Conference Call August 4, 2022 4:45 PM ET Company Participants James Hart - Vice President of Investor Relations Peter Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer Conference Call Participants Anne Samuel - JPMorgan Sarah James - Barclays Stephanie Davis - SVB Securities Dev Weerasuriya – Berenberg Capital Markets Operator Good afternoon, ladies and gentlemen, and welcome to today's Progyny Inc. Second Qu ...